Keyphrases
Venous Thromboembolism
100%
Direct Oral Anticoagulants
65%
Aspirin
61%
Atrial Fibrillation
60%
Platelets
60%
Anticoagulation
59%
Thrombocytopenia
59%
Thrombosis
49%
Thrombin Generation
45%
Bleeding
42%
Antiplatelet Therapy
39%
Procoagulant Potential
39%
Confidence Interval
37%
Low Molecular Weight Heparin
36%
Pregnancy Disorders
36%
Clopidogrel
36%
In Cancer
35%
Cancer Patients
34%
Clinical Outcomes
34%
Endogenous Thrombin Potential
32%
Patients with Hematological Malignancies
32%
Apixaban
29%
Type 2 Diabetes Mellitus (T2DM)
28%
Bleeding Risk
27%
Population-based Cohort Study
27%
Arterial Thromboembolism
26%
Hazard Ratio
26%
Platelet Count
25%
Hematological Malignancies
23%
Platelet Adhesion
23%
Recurrent Venous Thromboembolism
21%
Dose Adjustment
21%
Platelet Inhibition
21%
Platelet Activation
20%
Immune Thrombocytopenic Purpura
20%
Chemotherapy
19%
Antithrombotic Therapy
19%
Antiplatelet Agents
19%
Flow Condition
19%
Cumulative Incidence
19%
Type 2 Diabetic Patients
19%
Major Bleeding
18%
Cancer-related
18%
Malignant Superior Vena Cava Syndrome
18%
Fragility Hip Fracture
18%
COVID-19
18%
Percutaneous Coronary Intervention
18%
Clinical Vignette
18%
Non-pregnant Women
18%
Catheter-directed Thrombolysis
18%
Medicine and Dentistry
Venous Thromboembolism
93%
Malignant Neoplasm
79%
Platelet
75%
Anticoagulation
74%
Atrial Fibrillation
58%
Thrombocytopenia
58%
Thrombosis
54%
Bleeding
45%
Hematologic Malignancy
37%
Direct Oral Anticoagulant
34%
Thrombin
30%
Antiplatelet
30%
Procoagulant
29%
Apixaban
28%
Cohort Analysis
27%
Maturity Onset Diabetes of the Young
27%
Arterial Thromboembolism
26%
Disease
24%
COVID-19
24%
Meal
23%
Deep Vein Thrombosis
21%
Thrombocyte Activation
20%
Antithrombotic
19%
Cancer
18%
Major Bleeding
18%
Blood Clot Lysis
18%
Superior Vena Cava Syndrome
18%
Thrombotic Thrombocytopenic Purpura
18%
Disease Course
16%
Thromboprophylaxis
16%
Hazard Ratio
15%
Cancer Treatment
15%
Thrombocyte Adhesion
14%
Low Molecular Weight Heparin
14%
Type 1 Diabetes
13%
Cumulative Incidence
13%
Non Small Cell Lung Cancer
13%
Thromboembolism
13%
Acetylsalicylic Acid
12%
Thrombocyte Transfusion
12%
Infection
12%
Phlebothrombosis
11%
Drug Therapy
11%
Blood Stasis
11%
Fibrinogen
11%
Antithrombotic Therapy
11%
Idiopathic Thrombocytopenic Purpura
11%
CHA2DS2-VASc Score
11%
Computer Assisted Tomography
10%
Adenosine Diphosphate
10%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
77%
Acetylsalicylic Acid
68%
Malignant Neoplasm
62%
Atrial Fibrillation
61%
Antiplatelet
54%
Direct Oral Anticoagulant
49%
Thrombin
44%
Thrombocytopenia
44%
Bleeding
40%
Non Insulin Dependent Diabetes Mellitus
36%
Clopidogrel
35%
Thrombosis
32%
Antithrombocytic Agent
31%
Anticoagulant Agent
31%
Cohort Study
29%
Arterial Thromboembolism
29%
Procoagulant
28%
Adenosine Diphosphate
28%
Hematologic Malignancy
28%
Low Molecular Weight Heparin
26%
Disease
22%
Chemotherapy
21%
Hip Fracture
18%
Apixaban
18%
Thrombotic Thrombocytopenic Purpura
18%
Purinergic P2Y12 Receptor
15%
Acute Heart Infarction
14%
Antivitamin K
13%
Non Small Cell Lung Cancer
13%
Infection
13%
Arachidonic Acid
13%
Normal Human
13%
Flow Cytometry
12%
P-Selectin
12%
Polypharmacy
12%
Integrin
12%
Diabetes Mellitus
11%
Warfarin
11%
Antithrombotic Therapy
10%
SARS Coronavirus
10%
Acute Coronary Syndrome
10%
Disease Course
10%
Prasugrel
10%
Ticagrelor
10%
Insulin Dependent Diabetes Mellitus
9%
Vein Thrombosis
9%
Endometriosis
9%
Disease Severity
9%
Surgical Infection
9%
Microparticle
9%